stockrowDenali Therapeutics Inc.
DNLI Healthcare Biotechnology
Denali Therapeutics Inc.’s revenue for fiscal 2023 (year ended December 2023) was $330.5 million, up 204.7% from fiscal 2022.
- Revenue
- −94.0%
- EPS
- +150.3%
- Free cash flow
- −11.8%
- Total debt
- −1.89%
Quarter to September 2026, against a year earlier
Follow DNLI
Alert me
Denali Therapeutics Inc. (DNLI) Book value per share
Denali Therapeutics Inc.'s book value per share at the end of fiscal 2025 was 5.9×, down 21.5% from 7.5× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 4.9×. Over the past ten years it has ranged from 4.1× (fiscal 2019) to 39.6× (fiscal 2016); the current reading is higher than 18% of that period. Denali Therapeutics Inc. ranks 159th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 5.9× | (21.46%) |
| FY2024 | 7.5× | (0.38%) |
| FY2023 | 7.5× | (9.63%) |
| FY2022 | 8.3× | 4.87% |
| FY2021 | 7.9× | (25.00%) |
| FY2020 | 10.6× | 155.62% |
| FY2019 | 4.1× | (30.04%) |
| FY2018 | 5.9× | (81.03%) |
| FY2017 | 31.1× | (21.42%) |
| FY2016 | 39.6× | 264.45% |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 4.9× | 10.29% |
| Jun 2026 | 4.5× | (10.14%) |
| Mar 2026 | 5.0× | (15.49%) |
| Dec 2025 | 5.9× | 9.31% |
| 37 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| ELVN Enliven Therapeutics, Inc. compare | 13.5× |
| IDYA IDEAYA Biosciences, Inc. compare | 10.6× |
| VKTX Viking Therapeutics, Inc. compare | 5.0× |
| DNLI Denali Therapeutics Inc. | 4.9× |
| DYN Dyne Therapeutics, Inc. compare | 4.2× |
| TARS Tarsus Pharmaceuticals, Inc. compare | 2.2× |
| VRDN Viridian Therapeutics, Inc. compare | 0.0× |
| TLX Telix Pharmaceuticals Limited compare | 0.0× |
| CELC Celcuity, Inc. compare | −0.2× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on DNLI
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement